Navigation Links
Kendle Appoints Martha Feller, PhD, Vice President and Global Head, Study Start-up
Date:2/28/2011

CINCINNATI, Feb. 28, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced Martha R. Feller, PhD, has rejoined the Company as Vice President and Global Head, Study Start-up, effective immediately. Dr. Feller brings to Kendle more than 30 years of senior operations leadership in the clinical development industry, including broad therapeutic expertise and vast experience in managing large-scale, multimillion-dollar global development programs. In her new role Dr. Feller will provide leadership for the Company's global Study Start-up function – including Study Start-up Management, Site Identification, Site Start-up, Clinical Trial Regulatory, Investigator Contracts and Essential Document Collection – and will focus on fostering strong site relationships to optimize timelines and deliver rapid study start-up for global clinical trials.

"Timely and efficient study start-up on global projects is essential to our business success and ability to deliver best-in-class clinical development solutions to our customers," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "The appointment of an experienced industry veteran to lead this important function demonstrates our commitment to delivery of site selection and start-up strategies that provide valuable time-saving results for our customers."

Dr. Feller rejoins Kendle following two years with i3 Research where she served as Executive Vice President, Global Operations responsible for Phase I-III clinical programs. From 2004 to 2009 Dr. Feller held leadership roles in Kendle's Phase II-III clinical development operations, serving most recently as Senior Vice President, Global Clinical Development. Prior to joining Kendle, she spent 24 years with Procter & Gamble Pharmaceuticals where she held several senior-level positions, including Associate Director, New Drug Development, responsible for leading the company's global development and regulatory approval efforts for a new female testosterone patch therapy and Associate Director, Worldwide Regulatory and Medical Affairs, OTC. Dr. Feller earned a Doctorate in biochemistry from the University of Cincinnati College of Medicine and a Bachelor of Science in chemistry and mathematics from Edgecliff College (now part of Xavier University).

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995. Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated study start-up efficiencies, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of Feb. 28, 2011. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO
2. Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast
4. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
5. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
6. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
7. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
8. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
9. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
10. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
11. Kendle Launches New Global Biostatistics Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  LivaNova, PLC, Hersteller des VNS-Therapie ® ... Titel „Epilepsy Around the World" (Epilepsie auf ... gegenüber ein größeres Bewusstsein gefördert werden soll ... Epilepsie auf dem Internationalen Epilepsietag zu einem ... der neuen Infografik sollen wichtige Statistiken zur ...
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
Breaking Medicine Technology:
(Date:2/5/2016)... FL (PRWEB) , ... February 05, 2016 , ... ... the largest domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual ... awareness for kids and adults with muscular dystrophy, ALS and related diseases that ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators of ... direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque ... , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... WA (PRWEB) , ... February 05, 2016 , ... ... firm, ranked #3 in the 2015 Best in KLAS: Software & Services for ... The annual Best in KLAS report independently ranks vendor performance by healthcare executives, ...
Breaking Medicine News(10 mins):